From: TSH receptor antibodies have predictive value for breast cancer – retrospective analysis
Parameter | [Previously reported data] (n = number of patients enrolled to study) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[3] (n = 150) | [18] (n = 115) | [34] (n = 61) | [35] (n = 175) | [36] (n = 48) | |||||||||||
BC | C | p | BC | C | p | BC | C | p | BC | C | p | BC | C | p | |
n | 150 | 100 | - | 66 | 49 | - | 36 | 100 | - | 100 | 75 | - | 26 | 22 | - |
Age-yr means ± SD (min-max) | 63 (38–80) | age-matched | - | 63.5 ± 11.8 | 68.4 ± 12.8 | ns | 52.8 ± 10.2 | age-matched | - | 63 (38–80) | - | - | (30–85) | age-matched | - |
TSH | 3.12 ± 1.40 | 1.46 ± 0.82 | ns | 1.77 (0.15-47.9) | 1.52 (0.45-14.56) | ns | 1.9 ± 0.7 | 1.8 ± 1.4 | ns | 4.12 ± 1.40 | 1.39 ± 0.79 | 0.030 | 1.36 ± 0.63 | 2.41 ± 0.35 | <0.05 |
units | μIU/ml | mIU/dl | μIU/ml | μIU/ml | μU/ml | ||||||||||
FT 4 | 2.64 ± 0.91 | 1.42 ± 0.31 | ns | 15.70 (7.38-22.63) | 15.19 (10.5-21.5) | ns | 9.76 ± 2.73 | 9.9 ± 2.4 | ns | 2.93 ± 0.57 | 1.39 ± 0.21 | 0.030 | 1.40 ± 1.64 | 1.10 ± 0.83 | <0.05 |
units | ng/dl | pmol/dl | pg/ml | ng/dl | ng/dl | ||||||||||
FT 3 | 8.47 ± 0.75 | 4.48 ± 0.75 | ns | - | 3.58 ± 0.7 | 3.2 ± 0.6 | ns | 7.25 ± 0. 75 | 3.42 ± 0.91 | 0.030 | 3.56 ± 3.14 | 2.87 ± 3.12 | <0.001 | ||
units | pmol/l | pg/ml | pmol/l | pmol/ml | |||||||||||
TgAb | 140.92 ± 21.52 | 27.75 ± 7.60 | ns | 35.80 (26.1-6000.0) | 27.70 (18.5-298.0) | <0.001 | 12/36 | 12/100 | p < 0.01 | - | - | ||||
units | IU/ml | kIU/dl | Patients’ ratio with positive TgAb | ||||||||||||
TPOAb | 105.82 ± 21.46 | 23.08 ± 4.16 | 0.030 | 6.10 (6.1-871.0) | 6.10 (6.1-1621.6) | ns | 12/36 | 8/100 | p < 0.01 | 104.57 ± 19.39- | 24.81 ± 5.16 | 0.030 | - | ||
units | IU/ml | kIU/dl | Patients’ ratio with positive TPOAb | IU/ml | |||||||||||
Diagnosis | BC | C | p | BC | C | p | - | ||||||||
Graves’ disease | - | 0/66 | 0/49 | - | |||||||||||
AITD | 57/150 | 17/100 | 0.001 | 16/66 | 8/49 | - |